Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLS-012 + GLS-010
- Development stage
- Phase 2
- Lead developer
- Guangzhou Gloria Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GLS-012 + GLS-010 is a combination of two investigational monoclonal antibodies developed for the treatment of advanced solid tumors, including non-small cell lung cancer and melanoma. GLS-012 is an anti-LAG3 (lymphocyte activation gene 3) monoclonal antibody that acts as an immune checkpoint inhibitor by blocking LAG3-mediated T-cell inhibition, thereby enhancing antitumor immune responses. GLS-010, also known as zimberelimab, is a fully human anti-programmed death 1 (PD‑1) monoclonal antibody that blocks the PD‑1/PD‑L1 pathway to restore T-cell activity against tumor cells. The combination aims to provide synergistic immunotherapeutic effects by dual checkpoint blockade (LAG3 and PD‑1), potentially improving outcomes in patients with advanced cancers who have progressed on standard treatments. Both agents are administered intravenously every three weeks in clinical trials[2][5][7][6].
- Other names
- zimberelimab
02
Targets
LAG3 (Lymphocyte activation Gene-3 protein)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on GLS-012 + GLS-010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLS-012 + GLS-010.